Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Walvax to Gain Majority Control of Genor BioPharma for $49 Million

publication date: Dec 24, 2013
Walvax Biotech will acquire 64% of Shanghai’s Genor BioPharma via two transactions, paying a total of 290 million RMB ($49 million). Genor Biopharma, which was formed by China’s Wison Group conglomerate, specializes in MAbs and other biologic drugs. It develops its own drug candidates and partners with other biopharmas. Walvax intends to acquire 100% of Genor. In September, when rumors of the transaction first surfaced, it was also thought that Walvax would IPO Genor in the US. So far, that has not been confirmed. More details....

Stock Symbol: (SHE: 300142)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital